Key Highlights

  • Revenue of USD 8.28 million missed the USD 8.44 million estimate, and the loss was USD 0.45 per share.
  • Consumables Revenue rose 24% to USD 4.7 million, while software revenue fell 31% to USD 1.1 million.
  • Gross Margin was 48% against 46%, and operating expenses decreased 12% to USD 10.5 million.
  • Cash, cash equivalents and securities were USD 8.7 million, and the filing states substantial doubt about going concern.

Bionano Genomics, Inc. (NASDAQ:BNGO), a genome analysis company, reported third quarter 2026 revenue of USD 8.28 million, slightly below the USD 8.44 million estimate. The loss of USD 0.45 per share matched the estimate. Net loss was USD 6.5 million for the quarter and USD 22.2 million for the nine months.

Management said consumables revenue was USD 4.7 million, up 24% on sales to existing customers in the Americas. Software revenue was USD 1.1 million, down 31% on a lower number of VIA software licenses sold. Other revenue, which includes instruments and services, was USD 2.5 million, up 24%, led by higher instrument sales to new customers.

Regions, Margins and Guidance

Revenue in Europe, the Middle East and Africa grew 14% to USD 4.1 million from USD 3.6 million, and revenue in the Americas grew 35% to USD 3.8 million. The filing states instrument revenue rose USD 0.5 million, or 29%, to USD 2.1 million, and product Gross Profit rose USD 1.0 million, or 34%, to USD 4.1 million.

Gross margin was 48% against 46% a year earlier. Operating expenses decreased 12% to USD 10.5 million and adjusted operating expenses decreased 9% to USD 8.8 million. Management reiterated full year 2026 revenue guidance of USD 31 million to USD 33 million, representing growth of 9% to 16%.

Going Concern Note and Cash

The filing states the accumulated Deficit was USD 741.8 million at September 30, 2026. It states that, based on recurring losses from operations since inception, the expectation of continued operating losses and the need to raise additional capital, the company determined there is substantial doubt about its ability to continue as a going concern.

The company ended the quarter with USD 8.7 million in cash, cash equivalents and available-for-sale securities, including USD 0.5 million subject to certain restrictions. Management said that as revenue grows and its mix shifts toward higher-margin consumables and software, it anticipates trends carrying it toward adjusted EBITDA neutrality by the end of 2027.

Items to Follow

Operating expenses of USD 10.5 million compare with adjusted operating expenses of USD 8.8 million, which exclude certain items. Management also noted that two leading academic centers in New York are bringing optical genome mapping into their clinical laboratories. Management also said gross margin in 2023 was in the low 20% range, so the 48% margin in the third quarter reflects a longer improvement trend. The items to follow are consumables growth, software license sales, operating expenses, financing and the cash balance. Legal items in the quarterly filing are reported there and flagged for human legal review.